6% CONVERTIBLE DEBENTURE DUE NOVEMBER 28, 2019Microbot Medical Inc. • November 29th, 2016 • Biological products, (no disgnostic substances) • New York
Company FiledNovember 29th, 2016 Industry JurisdictionTHIS 6% CONVERTIBLE DEBENTURE is one or more of a series of duly authorized and validly issued 6% Convertible Debentures of Microbot Medical Inc. (formerly known as Stemcells, Inc.), a Delaware corporation (the “Company”), having its principal place of business at 5 Hamada Street, Yokneam 2069204 Israel, designated as its 6% Convertible Debenture due November 28, 2019 (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
SECURITIES EXCHANGE AGREEMENTSecurities Exchange Agreement • November 29th, 2016 • Microbot Medical Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 29th, 2016 Company Industry JurisdictionThis Securities Exchange Agreement (this “Agreement”) is dated as of November 28, 2016, between Stemcells, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • November 29th, 2016 • Microbot Medical Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledNovember 29th, 2016 Company Industry JurisdictionINDEMNIFICATION AGREEMENT (“Agreement”), which provides for indemnification, expense advancement and other rights under the terms and conditions set forth, is made and entered into this [ ] day of November, 2016, between Microbot Medical Inc. (f/k/a StemCells, Inc.; the “Company”), and [ ] (“Indemnitee”).